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AbstrAct
Asymptomatic Alzheimer’s disease (ASYMAD) subjects are individuals 
characterized by preserved cognition before death despite substantial AD pathology 
at autopsy. ASYMAD subjects show comparable levels of AD pathology, i.e. 
β-amyloid neuritic plaques (Aβ-NP) and tau-neurofibrillary tangles (NFT), to those 
observed in mild cognitive impairment (MCI) and some definite AD cases. Previous 
clinicopathologic studies on ASYMAD subjects have shown specific phenomena 
of hypertrophy in the cell bodies, nuclei, and nucleoli of hippocampal pyramidal 
neurons and other cerebral areas. Since it is well established that the allele APOε4 
is a major genetic risk factor for AD, we examined whether specific alleles of APOE 
could be associated with the different clinical outcomes between ASYMAD and MCI 
subjects despite equivalent AD pathology. A total of 523 brains from the Nun Study 
were screened for this investigation. The results showed higher APOε2 frequency 
(p < 0.001) in ASYMAD (19.2%) vs. MCI (0%) and vs. AD (4.7%). Furthermore, 
higher education in ASYMAD vs. MCI and AD (p < 0.05) was found. These novel 
autopsy-verified findings support the hypothesis of the beneficial effect of APOε2 and 
education, both which seem to act as contributing factors in delaying or forestalling 
the clinical manifestations of AD despite consistent levels of AD pathology.
IntroductIon
Many decades of clinicopathologic investigations 
on sporadic Alzheimer’s disease (AD) have enormously 
contributed to the definition of the main pathologic lesions 
associated with AD, i.e. β-amyloid neuritic plaques (Aβ-
NP) and tau-neurofibrillary tangles (tau-NFT), and to a 
better understanding of the possible relationships between 
cognitive deficits and AD lesions [1, 2]. However, the 
exact mechanisms leading to those pathologic hallmarks 
of AD (Aβ-NP, tau-NFT) and how they determine 
neuronal degeneration in specific areas of human brain 
(i.e., entorhinal cortex, hippocampus) yet remain to be 
yet completely clarified [3-5]. The hypothesis that Aβ-
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NP, tau-NFT, as well as Aβ or tau oligomers, are the 
only responsible factors for the cognitive declining in 
AD has not been satisfactorily confirmed by a series of 
neuropathologic, neuroimaging, and biochemical studies 
attempting to establish linear correlations between AD 
pathology and cognitive decline [6-12]. One of the most 
convincing evidences of the absence of linearity between 
cognitive deficits and AD pathology is the frequent 
observation, at autopsy, of a considerable number of older 
individuals with high burdens of Aβ-NP and tau-NFT 
with preserved cognition as assessed shortly prior to death 
(i.e. < 1 year). These older individuals with preserved 
cognition and consistent amounts of AD pathology at 
autopsy have been termed asymptomatic AD (ASYMAD) 
subjects. ASYMAD subjects not only have comparable 
levels of AD pathology to those found in mild cognitive 
impairment (MCI) subjects and some definite AD patients 
but also have an identical cerebral localization [13, 15]. 
Other investigators referred to ASYMAD under different 
appellations, such as “high pathology controls” [16] or 
“preclinical AD” [17]. Those investigators essentially 
referred to the same concept: there are older individuals 
cognitively silent for AD even with consistent levels of AD 
pathology at autopsy. This clinicopathologic dissociation 
has also been described employing “in vivo” functional 
neuroimaging studies [18-22]. 
The reason to term older individuals cognitively 
preserved but positive for AD pathology at autopsy 
using the acronym ASYMAD is because it is virtually 
impossible to know “a priori” whether these subjects 
would have remained cognitively preserved or eventually 
would have progressed to MCI or AD had they lived 
longer. The term ASYMAD then has the advantage to 
not imply necessarily a forthcoming or future cognitive 
decline [23]. In addition, the ASYMAD term can be easily 
applied to other fields of AD and aging research, such as 
functional neuroimaging [24]. 
It is significant to recall here that a clinicopathologic 
dissociation between AD pathology and cognition was 
already recognized a few decades ago [25-31] without 
receiving, unfortunately, any major scientific attention. 
Recently however, the discrepancy between cognitive 
aspects and AD pathology has been implicitly accepted 
by newer AD pathologic criteria [32, 33]. These criteria 
do not require a diagnosis of dementia to stage the 
AD pathology at autopsy. They “simply” propose a 
probabilistic scoring system for the AD neuropathologic 
changes, which uses previously established systems of 
Aβ-NP and NFT staging without taking into account any 
clinical or dementia history of the subject that received 
the autopsy.
In previous studies [34-37], a marked neuronal 
hypertrophy in different cerebral regions of ASYMAD 
subjects vs. age-matched controls (C), MCI and AD 
subjects was measured. These cellular changes have been 
hypothesized to be possible neuronal reactions or part 
of compensatory mechanisms facing the accumulation 
of AD pathology, which would allow normal cognitive 
functioning despite abundant AD pathology. In agreement 
with this compensatory hypothesis, phenomena of 
neuroplasticity have been described by functional 
neuroimaging studies enrolling MCI and early-AD 
patients and also, importantly, high-risk subjects for AD, 
that is subjects without cognitive signs of the disease [37-
41]. 
This new clinicopathologic investigation aimed 
to go beyond the morphometric characterizations [35, 
36] and quantitative measurements of AD pathology in 
ASYMAD vs. Controls, MCI, and definite AD [42] and 
possibly describe other contributing factors which could 
underlie the cognitive resilience of ASYMAD subjects 
despite AD pathology.
There are very few large epidemiological studies that 
include analyses of normal aging and AD, and an autopsy 
program. Among those rarer epidemiological studies, 
the Nun Study has been a historical one [43]. Rendering 
use of the wealth of longitudinal clinical information 
and rigorous pathological observations available from 
the Nun Study [43, 44], we aimed to analyze the allelic 
frequencies of APOE gene (APOE) and the attained 
education levels of the entire available sample of this 
unique autopsy-cohort. APOε2, one of the three alleles 
of APOE [45], and higher education levels have been 
shown to have protective capacities against AD [46, 47]. 
The principal aim and novelty of this investigation was 
to verify if APOε2 frequency and education levels were 
indeed significantly higher in ASYMAD subjects from the 
Nun Study. An adjunctive potential novelty of this study 
consisted in the opportunity to associate those possible 
findings on the protective effects of APOε2 and higher 
education taking also into account previously described 
phenomena of neuronal hypertrophy in ASYMAD subjects 
from the same study [37], as well as their association to 
higher language skills acquired early in life. Higher early-
acquired language skills have been demonstrated to reduce 
the risk of dementia [48-49]. 
results
Demographic, educational, cognitive, 
neuropathologic, and APOE allele distribution data across 
groups are summarized in Table 1. Statistical analyses did 
not show differences for the mean age at death, age at last 
cognitive assessment, and Cog-Death interval across all 
groups. BW was not different among ASYMAD, MCI, 
and C, although the mean BW was lower in AD compared 
with all other groups. 
ASYMAD and C did not differ for the last MMSE 
and ADLs mean scores. By contrast, AD showed 
significantly lower MMSE and ADLs mean scores 
compared to all other groups. 
Aβ-NP CERAD scores showed no statistical 
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difference between ASYMAD and MCI, whereas 
differences were found between ASYMAD and AD (p 
< 0.05); and between MCI and AD (p < 0.05). Braak-
NFT scores were different across comparisons when all 
stages (0-VI) were considered: ASYMAD vs AD (p < 
0.001), MCI vs AD (p < 0.01), and ASYMAD vs MCI 
(p < 0.05). However, when the analysis of Braak staging 
was performed including only the first five stages (0-IV), 
no differences were observed between ASYMAD vs. MCI 
and even between MCI and AD. 
Higher APOε2 frequency was found in ASYMAD 
(19.7%) compared to MCI (0%, p < 0.01) and AD (4.7%, 
p < 0.01). No different APOε2 frequency was detected 
between ASYMAD and C (13.6%). While no differences 
were observed in APOε3 frequency across all groups, 
lower APOε4 frequency was observed in ASYMAD 
(3.8%) compared to MCI (30.0%, p < 0.01) and AD 
(19.4%, p < 0.01). Importantly, no different APOε4 
frequency was found between ASYMAD and C (0%). All 
comparisons for APOE allelic frequencies are shown in 
Figure 1.
Moreover, APOε2 frequency was significantly 
higher (p = 0.004) in PCG (C+ASYMAD, ε2 = 16.6%) 
compared to ICG (MCI+AD, ε2 = 4.2%) (Figure 2). By 
contrast, whereas APOε3 frequency did not show any 
difference between these two groups, APOε4 frequency 
was significantly higher (p = 0.001) in ICG (ε4 = 20.6%) 
compared to PCG (ε4 = 2.0%).
The analyses show significant differences on 
education levels between PCG compared to ICG (p = 0.02) 
group. Correlation analyses (Spearman’s test) between 
APOε2 and the highest level of attained education (master 
or higher), however, did not show significant correlations 
across all groups, or any other possible correlation 
between groups comparison.
dIscussIon
The most important findings of this 
clinicopathologic study are: a) higher APOε2 frequency 
and b) higher educational levels in ASYMAD vs. MCI 
and AD. These findings suggest a beneficial effect of 
table 1: demographic, educational, cognitive, neuropathologic, and APoe frequencies of 155 subjects with autopsy-
confirmed diagnosis and interval Cog-Death ≤1.0 year
controls
(n = 11; 7.1%)
AsYMAd
(n = 13; 8.3%)
McI
(n = 15; 9.6%)
Ad
(n = 116; 74.8%)
Interval cog-death (years) 0.5±0.2 0.50.2 0.5±0.2 0.40.2 
Age at death (years) 86.9±5.7 89.5±2.1 89.4±4.5 92.2±4.6
Age at last cog (years)* 86.4±5.8 89.0±2.3 88.8±4.5 91.7±4.6
Last MMSE* 27.8±1.3 28.3±1.1 26.0±1.4 8.0±8.1
ADLs* 5.0±0.0 5.0±0.0 4.7±0.4 0.9±1.5
Education (%)
              Grade school only 
              High school diploma 
              bachelor degree  
              Masters or higher
0.0
0.0
36.6
63.4
7.6
0.0
30.7
61.5
6.6
0.0
60.0
33.3
16.3
7.7
46.5
29.3
Brain weight (grams) 1182.2±259.3 1144.5±80.5 1170.3±110.9 1083.9±117.1
CERAD score (%)*
               0 
               b
               c
100
0
0
0.0
76.9
23.0
0.0
73.3
26.6
0.0
41.3
58.6
NFT Braak score (%)*
               0
               I
               II
               III
               IV
               V
               VI
18.1
27.2
54.5
0.0
0.0
0.0
0.0
0.0
15.3
69.2
15.3
0.0
0.0
0.0
0.0
6.6
33.3
6.6
20.0
33.3
0.0
0.8
3.4
12.0
12.0
11.2
22.4
37.9
ε2 allele frequency (%)* 13.6 19.2  0 4.7
ε3 allele frequency (%) 86.3 76.9 70.0 75.8
ε4 allele frequency (%)* 0 3.8 30.0 19.4
*Differences across groups were significant at p<0.01. Controls: age-matched controls; ASYMAD: asymptomatic AD 
subjects; MCI: mild cognitive impairment subjects; AD: Alzheimer’s disease patients. The interval Cog-Death (the interval 
of time between the last cognitive assessment and death), age at death, age at last cognitive exam, last MMSE, ADLs, and 
brain weight are expressed as mean±SD. The first row of the table shows the sample size (n and percentages) of each group 
respect to the total sample size (n = 155) of the study. The table shows also the single APOE allele (ε2, ε3, and ε4) frequencies 
for each group.  
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APOε2 and education on later cognition even in presence 
of AD pathology burdens that are equivalent to those 
found in the MCI and some definite AD cases. Previous 
epidemiological studies have reported a protective role of 
APOε2 [46] and higher education [60] against AD, but 
only few have been confirmed by autopsy findings [61]. To 
the best of our knowledge, this is the first clinicopathologic 
study showing a significant association between higher 
APOε2 frequency and higher education in a cohort of 
autopsy-confirmed ASYMAD vs. MCI, and AD subjects. 
Moreover, from the same autopsy-cohort, a previously 
examined group of ASYMAD subjects was associated 
with specific cellular morphometric changes, such as 
neuronal hypertrophy in CA1 of hippocampus and higher 
language skills acquired in early life [37]. Unfortunately, 
the limited availability of hippocampi from all autopsy 
cases of this study did not allow to verify those significant 
correlations among CA1-neuronal hypertrophy, APOε2, 
and education/language across the entire autopsy-cohort. 
However, this investigation seems to offer important 
seminal perspectives on the possible interaction among 
AD pathology, APOE genotypes, education/language, 
and mechanisms of neuroplasticity. These intriguing 
cognition-pathology-genotype-neuroplasticity correlations 
remain to be verified by future larger autopsy-studies. 
However, a recent non-autopsy study confirmed our 
previous findings [37] on the beneficial effect of APOε2 
on lifetime experiences enhancing cognition, which was 
better indicated by measuring specific linguistic skills (i.e., 
vocabulary and reading ability) [62].
In terms of pathogenic sequence, our findings 
suggest that the possible beneficial effects of APOε2 
and higher education lie downstream to both Aβ and tau 
depositions, and are possibly linked to multiple biological 
mechanisms [63-64]. A recent larger neuropathologic study 
[65], which analyzed a larger amount of pathologic and 
clinical data from the National Alzheimer’s Coordinating 
Center (NACC) dataset, had the chance to stratify a higher 
number of subjects based on their levels of AD pathology 
and clinical manifestation. Their findings are in line 
Figure 1: The figure shows histograms for the frequency distribution of APOε2, ε3, and ε4 alleles in the four different groups 
examined in the study. 
Figure 2: The figure shows the histograms for APOε2 frequencies and educational levels in two different groups: 1) preserved 
cognition group (PCG): controls+ASYMAD subjects; and 2) impaired cognition group (ICG): MCI+AD patients. The p-values 
are the statistical significance values after exact Fisher’s test.
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with ours regarding the protective effect of APOε2 even 
after adjustments for influencing factors such as the age 
of onset, duration of symptoms, and other demographic 
variables. Although the nature of the population analyzed 
in this larger study [65] is different from ours, the findings 
are impressively similar. Moreover, our findings not only 
seem to confirm the results from a larger study [65] but 
also extend them. In fact, the novelty of our investigation 
consists not only in supporting that ASYMAD are subjects 
associated with higher APOε2 frequency and education 
but also with specific morphometric-neuronal changes 
[37] and cognitive skills, such as higher early-acquired 
language skills [37, 48, 49].
Moreover, experimental studies indicate that APOε2 
has a protective role in both the peripheral and central 
nervous system [66, 67]. Furthermore, data describe 
APOε2’s enhancing capacity to increase neuritic growth 
in contrast to APOε4 which demonstrates a detrimental 
effect on it [68, 69]. 
Remarkably, APOε3 frequency was not different 
across all groups in our investigation. This suggests that 
it is actually the interplay between APOε2 and APOε4 to 
weigh heavily on the risk of developing MCI and AD, 
or remaining cognitively unscathed. Importantly, only 
the presence of APOε2 is insufficient to avoid the AD 
pathology deposition, as demonstrated by the conspicuous 
amount of it in ASYMAD subjects. APOε2, rather, seems 
to have beneficial properties in reducing the consequences 
of AD pathology accumulation or even in reducing it [70].
APOE distribution in the Nun Study is similar 
to that of Caucasian populations [71]. However, it is 
important to emphasize that APOε2 frequency in this Nun 
Study autopsy-cohort was curiously higher (19.2%) than 
that observed in Caucasians (2-8%). This could be related 
to the possible role of APOε2 on survival and longevity 
[72-74]. The involvement of APOε4 as risk factor for 
cardiovascular diseases [75] and enhanced innate immune 
response [76], could exclude these subjects from normal 
aging and AD longitudinal studies.
How common is ASYMAD? In our series, out of 
24 cognitively preserved subjects (C+ASYMAD) older 
than 85 years (mean age = 88.2±3.9), 54.0% showed 
severe levels of AD pathology but unimpaired cognition 
(ASYMAD). A previous large autopsy-cohort study [77] 
showed that 30% of subjects diagnosed with probable 
AD have insufficient AD neuropathological changes at 
autopsy to satisfy a diagnosis of definite AD. While those 
data showed insufficiency of AD pathology to explain the 
dementia in a high number of subjects, we substantiate 
that even with equivalent amounts of AD pathology, other 
factors such as APOε2, education, and early acquired 
language/cognitive skills [33] are indeed associated with 
a decreased risk, delay, or even avoidance of dementia. 
It is not possible to transfer our findings to the 
general population without caveats. We cannot exclude 
that the higher educational levels of the Nun Study 
participants contributed to a higher “cognitive reserve” 
[78]. In the Nun Study though, this issue could be less 
of a challenge since all sisters shared the lifestyle 
and comparable medical care. Other caveats could 
be the exclusion of those factors that can also impair 
the cognition: cerebro-vascular hypoxic phenomena, 
metabolic disorders, diabetes, hyperlipidemia, untreated 
hypertension, hypercaloric diet, alcohol abuse, or 
environmental and lifestyle stressors. It is neither possible 
to exclude that two brains can have similar numbers of 
Aβ-NP and NFT, but one brain has a higher concentration 
of toxic and specific soluble Aβ or tau oligomers than 
the other [12], and its risk of functional impairment 
is therefore enhanced. Genetic factors different from 
APOE and non-genetic factors different from education 
could also mutually interact. Complex gene-environment 
interactions, in fact, seem to determine an increased or 
decreased risk of dementia later in life. Recent studies 
on twins describe, for example, that even identical twins 
can differ in their onset of dementia and have different 
amounts of AD pathology at autopsy [79]. 
MAterIAls And MetHods
Subjects were identified by querying the database of 
the Nun Study, which includes clinical and cognitive data, 
educational information, neuropathologic evaluations with 
definite diagnoses, and APOE genotypes. Participants in 
the Nun Study are Catholic sisters belonging to the School 
Sisters of Notre Dame congregation living in various 
communities in the Midwestern, eastern, and southern 
regions of the US [43]. At the time of the enrollment period 
all sisters born before 1917 were asked to participate in the 
study. Of 1027 eligible sisters (aged 75 years or older), 
678 (66.0%) agreed to participate in the study. All sisters 
participating in the study signed an informed written 
consent form and agreed to annual physical and cognitive 
assessments and review of their medical records. They 
also consented to donate their brains for research after 
death. The Nun Study autopsy procedures were approved 
by the University of Kentucky’s Institutional Review 
Board. In 2010, the Nun Study moved back to its original 
Institution, the University Of Minnesota. 
In the present investigation only the participants that 
underwent autopsy were considered. The total sample size 
of the cohort with brain autopsy available was 523, that 
is, the 77.1% of the entire eligible cohort. The methods 
used to assess the cognitive status have been described 
in previous publications [50]. Briefly, the cognitive test 
battery included measures compiled by the Consortium 
to Establish a Registry for Alzheimer’s disease (CERAD) 
[51], which assesses memory, language, visuo-spatial 
ability, concentration, and orientation. In the Nun Study, 
this neuropsychological battery was administered by two 
trained gerontologists. Five of the tests from the CERAD 
battery were used to define preserved cognitive function: 
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Mini-Mental State Exam (MMSE), Delayed Word Recall, 
Boston Naming, Verbal Fluency, and Constructional 
Praxis. The standard cut point of 24 or greater was used 
to identify intact scores for the MMSE. For the other four 
tests, cut points that were close to, but did not exceed the 
5th percentile for the normative data described by the 
CERAD group [52], were identified to classify individual 
test scores as intact or impaired. The cut points for intact 
scores were as follows: ≥13 for Boston Naming, ≥11 
for Verbal Fluency, ≥4 for Delayed Word Recall, and 
≥8 for Constructional Praxis. Participants judged to 
be cognitively intact in the present analyses had intact 
scores on all five tests. Individuals who were classified 
as demented in the study had each of the following 
conditions: (a) impairment in memory and in at least one 
other area of cognition, (b) impairment in social or daily 
function (i.e., inability to use a phone, handle money, or 
dress oneself), and (c) decline in function from a previous 
level (observed during our study for the incident dementia 
cases, or inferred for those dementia cases present at 
the first exam). From the above described battery, the 
following classification system was established to define a 
subject cognitively as:
Intact (Preserved) Cognition: intact scores on all 
cognitive tests and activities of daily living (ADL). This 
category defined the cognition level of both age-matched 
controls (C) and ASYMAD subjects. 
Mildly Impaired Cognition (with memory 
impairment): intact on MMSE and ADL, but impaired on 
the Delayed Word Recall and one or more of the other 
three cognitive tests. This category is equivalent to mild 
cognitive impairment (MCI) subjects based on Mayo 
Clinic and AA-NIA MCI criteria [53, 54].
Demented: met clinical criteria for dementia as 
described above.
neuropathologic material and methods
The Nun Study had neuropathological data on a total 
of 523 autopsy brains. These brains were removed and 
examined macroscopically after fixation in 10% buffered 
formaldehyde for at least 2 weeks. Tissues blocks were 
dissected from middle frontal gyrus, superior and middle 
temporal gyri, inferior parietal lobule, occipital cortex 
(area 17-18), entorhinal cortex, hippocampus, amygdala, 
thalamus, basal ganglia and cerebellum. Tissue blocks 
were processed and embedded in paraffin, cut at 10 μm, 
and stained with hematoxylin-eosin (H&E) and Hirano-
silver method. The severity of Aβ-NP was assigned by 
semi-quantitative and age-adjusted scores (0, A, B, or 
C) according to CERAD pathologic criteria [55], and 
NFT stages were scored (0-VI) according to Braak-NFT 
system [56]. Out of the total of 523 autopsies, subjects 
were selected only if the following criteria were satisfied: 
1) Subjects with complete physical, neurologic, and 
cognitive assessment in an interval prior to death (Cog-
Death interval) of ≤1.0 year.
2) Neuropathologic assessments including CERAD 
pathologic diagnostic and Braak-NFT scores
3) Availability of APOE genotype.
Subjects were excluded if:
1) Met the criteria for mixed dementia. This 
exclusion criteria was particularly important to minimize 
the influence of cerebro-vascular pathologies on the 
cognitive deficits. 
2) Met the criteria for dementia with Lewy bodies, 
Parkinson’s disease with dementia, Pick’s disease, 
Creutzfeldt-Jacob disease. 
3) Showed hippocampal sclerosis, tauopathies, or 
primary or secondary brain tumors. 
Based on the clinical, cognitive, and neuropathologic 
assessment and above described inclusion/exclusion 
criteria, we identified a total of 155 subjects suitable for 
this study. These subjects were assigned to four study 
groups: 
1) Age-matched controls (C): subjects with intact 
cognition and no significant AD pathology at autopsy 
(CERAD = 0; Braak 0-II) (n = 11);
2) Asymptomatic AD (ASYMAD): subjects with 
intact cognition and AD pathology at autopsy (CERAD: 
B-C; Braak 0-VI) (n = 13);
3) Mild cognitive impairment (MCI): subjects with 
MCI diagnosis and AD pathology at autopsy (CERAD: 
B-C; Braak: 0-VI) (n = 15);
4) Alzheimer’s disease (AD), patients with clinical 
dementia and diagnosis of definite AD at autopsy 
(CERAD: B-C; Braak: 0-VI) (n = 116).
We decided not to classify these cases with neither 
NIA-Reagan criteria [57] nor AA-NIA criteria [58]. The 
reasons for this were: 
1) NIA-Reagan criteria apply to autopsy cases 
with previously ascertained dementia, then per se, not 
applicable to C or ASYMAD;
2) AA-NIA pathologic criteria do not take into 
account the diagnosis of dementia to stage neuropathologic 
AD changes, so excluding an important aim of our 
study: analyzing the presence or absence of cognitive 
impairment as related to AD pathology, APOE genotype 
and educational levels.
Moreover, NIA-Reagan and AA-NIA criteria are 
probabilistic systems of classification relying on Aβ-NP 
and NFT scores with the assumption that a cumulative 
pathogenetic contribution to AD pathogenesis is actually 
originating from both types of pathology. This assumption 
has not been demonstrated yet. Although NIA-Reagan 
and AA-NIA criteria have an undoubted practical utility 
in a clinical setting, in this investigation we preferred to 
consider CERAD and Braak scores separately. This choice 
was also useful to verify possible distinct cognitive-
pathologic-genotype correlations as subjacent to different 
pathogenetic mechanisms, such as Aβ-NP or NFT 
formation. 
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APoe genotyping
APOE genotype analyses on all study subjects have 
been conducted on DNA isolated from buccal swabs 
(archival) or from brain tissues as previously described 
[59].
statistical analyses
ANOVA was used to compare continuous variables 
(i.e. mean age at death, mean age at last cognitive 
examination before death, mean score of the last MMSE, 
mean scores of ADLs, and mean brain weight [BW]) 
across all groups; while Fisher’s exact test was used to 
compare categorical variables (i.e. CERAD pathological 
scores, Braak-NFT staging, and educational levels 
attained). 
For APOE allelic frequency analyses, we used 
Fisher’s exact test for a 3-by-4 contingency table 
comparing the frequencies of all three APOE allele across 
all groups. Then, we carried out analyses to examine the 
hypothesis that APOε2 was enriched in ASYMAD by 
conducting additional Fisher’s exact test to compare the 
frequencies of APOε2 vs. all other alleles in ASYMAD vs 
MCI, AD, and C, separately. 
In addition, an exact Fisher’s test was performed 
to compare the APOE allelic frequencies in two larger 
combined groups: 1) subjects with cognitive deficits 
(MCI+AD) (impaired cognition group, ICG); and 2) 
subjects without cognitive deficits (C+ASYMAD) 
(preserved cognition group, PCG). This analysis was 
performed to investigate possible effects of APOε2 
exclusively based on the documented cognitive assessment 
shortly before death. Separate analyses using an exact 
Fisher’s test were performed to compare ICG and PCG on 
the highest educational level attained. Finally Spearman’s 
test for nonparametric data (APOε2 frequencies) and 
highest level of education attained (master or higher) 
across all groups, expressed as percentages, was also 
performed to test if significant correlation between APOε2 
and higher education was possibly present.
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